Lafamme

Dienogest, the active ingredient in Lafamme, is a combined oral contraceptive presented as a tablet for oral use. Together with estradiol valerate, it provides both progestogenic and estrogenic activity to prevent ovulation, alter cervical mucus, and stabilize the endometrium, thereby preventing pregnancy and assisting in the regulation of menstrual cycles for women of reproductive age.

GNH USA supplies Lafamme as a licensed, GDP‑compliant international pharmaceutical supplier, providing reliable access to hospitals, pharmacies, and clinics worldwide through stringent quality assurance and regulatory compliance.

Lafamme, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy and manage menstrual disorders. - Contraception: prevents ovulation and pregnancy by suppressing the luteinizing hormone surge. - Menstrual cycle regulation: provides more predictable bleeding patterns and reduces dysmenorrhea. - Polycystic ovary syndrome (PCOS): helps normalize hormonal balance and regularize periods.

Lafamme may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset often occurring at treatment initiation. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: mild to moderate headaches that usually resolve with continued use. - Breakthrough bleeding: irregular spotting between periods. - Weight change: slight increase or decrease in body weight.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs, requiring immediate medical attention. - Arterial thrombosis: clot formation in arteries, which can lead to stroke or heart attack. - Severe allergic reaction: rash, swelling, or difficulty breathing indicating anaphylaxis.

Before prescribing Lafamme, clinicians should evaluate patient history and consider specific safety measures. - Contraindicated in active thromboembolic disease: avoid use in patients with current deep vein thrombosis or pulmonary embolism. - Smoking over 15 cigarettes per day: increased cardiovascular risk, especially in women over 35. - History of hormone‑dependent tumors: avoid in patients with breast, ovarian, or endometrial cancer. - Uncontrolled hypertension: monitor blood pressure and discontinue if severe. - Liver disease: use with caution in patients with severe hepatic impairment. - Store below 25°C: keep tablets in original packaging, protect from moisture and light.

Lafamme can interact with other medications, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): may increase clotting risk and require dose adjustment. - Protease inhibitors (e.g., ritonavir): can decrease hormone levels, compromising protection. - St. John’s wort: herbal inducer that lowers oral contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs (e.g., phenytoin): may modestly reduce hormone levels, monitor cycle control. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of mood changes or breast tenderness.